Oncology

Featured

Videos

Pembrolizumab Plus Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

04/24/2026

Emese Zsiros, MD, PhD, discusses results from the phase 3 KEYNOTE-B96 trial, which demonstrated that pembrolizumab improves survival while maintaining quality of life in patients with platinum-resistant ovarian cancer.

Emese Zsiros, MD, PhD, discusses...

04/24/2026

Oncology

News

Lorlatinib Shows Real-World Promise in in ALK-Positive Non-Small Cell Lung Cancer

04/24/2026

Emily Estrada

Real-world data demonstrate that lorlatinib provides high response and durable disease control in advanced ALK-positive NSCLC, with exploratory lipid biomarkers potentially predicting response.

Real-world data demonstrate that...

04/24/2026

Oncology

News

First-Line Daraxonrasib Plus Gemcitabine and Nab-Paclitaxel Shows Promisie in RAS-Mutated Metastatic Pancreatic Cancer

04/24/2026

Emily Estrada

Results from a phase 1/2 study demonstrate that first-line daraxonrasib plus gemcitabine and nab-paclitaxel shows strong preliminary efficacy and safety in RAS-mutated metastatic pancreatic cancer.

Results from a phase 1/2 study...

04/24/2026

Oncology

News

Amivantamab Plus Lazertinib Improves First- and Second-Line Outcomes in EGFR-Mutated NSCLC

04/23/2026

Stephanie Holland

Post hoc analysis results from the MARIPOSA trial demonstrate that first-line amivantamab plus lazertinib improves second-line outcomes compared with osimertinib in EGFR-mutated non-small cell lung cancer.

Post hoc analysis results from...

04/23/2026

Oncology

News

First-Line Daraxonrasib Shows Early Activity in RAS-Mutated Metastatic Pancreatic Cancer

04/23/2026

Stephanie Holland

Results from a phase 1/2 study demonstrate that first-line daraxonrasib shows encouraging clinical efficacy and safety in RAS-mutated metastatic pancreatic ductal adenocarcinoma.

Results from a phase 1/2 study...

04/23/2026

Oncology

Videos

Tumor Microenvironment Challenges in Refractory Metastatic Colorectal Cancer (mCRC): An Expert Debate

04/23/2026

Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD

The management of refractory metastatic colorectal cancer (mCRC) remains constrained by a biologically resistant, immune-excluded tumor microenvironment. In this peer-led debate, experts examine how tumor...

The management...

04/23/2026

Oncology

Videos

Round 1: Do Current Therapies Biologically Alter Refractory mCRC?

04/23/2026

Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD

04/23/2026

Oncology

Videos

Round 2: Are We Adequately Targeting the TME in mCRC?

04/23/2026

Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD

04/23/2026

Oncology

Videos

Round 3: Are We Adequately Stratifying mCRC Tumors to Inform Therapy?

04/23/2026

Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD

04/23/2026

Oncology

Videos

Introduction: Are We Meaningfully Impacting the Tumor Microenvironment?

04/22/2026

Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD

04/22/2026

Oncology

News

Mirvetuximab Plus Carboplatin Demonstrates Promise in Platinum-Sensitive Ovarian Cancer

04/21/2026

Stephanie Holland

Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.

Results from the phase 2...

04/21/2026

Oncology

Featured

Video Series on Updates in Clinical Development of Next-Generation Radioligand Therapies Streaming Now

Leading oncology experts discuss investigational somatostatin receptor–targeted radiopharmaceuticals and how emerging data may influence patient selection, treatment sequencing, and safety in neuroendocrine tumor care. Watch video 1 now!

Videos

Pembrolizumab Plus Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

04/24/2026

Emese Zsiros, MD, PhD, discusses...

04/24/2026

Oncology

Videos

Tumor Microenvironment Challenges in Refractory Metastatic Colorectal Cancer (mCRC): An Expert Debate

04/23/2026

Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD

The management...

04/23/2026

Oncology

Videos

Round 1: Do Current Therapies Biologically Alter Refractory mCRC?

04/23/2026

Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD

04/23/2026

Oncology

Videos

Round 2: Are We Adequately Targeting the TME in mCRC?

04/23/2026

Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD

04/23/2026

Oncology

Videos

Round 3: Are We Adequately Stratifying mCRC Tumors to Inform Therapy?

04/23/2026

Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD

04/23/2026

Oncology

Videos

Introduction: Are We Meaningfully Impacting the Tumor Microenvironment?

04/22/2026

Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD

04/22/2026

Oncology

Videos

Emerging Therapeutic Options for Patients With Relapsed/Refractory Multiple Myeloma

04/21/2026

Sikander Ailawadhi, MD

Sikander Ailawadhi, MD, discusses the rapidly evolving treatment landscape for patients with multiple myeloma.

Sikander Ailawadhi, MD,...

04/21/2026

Oncology

Videos

FDA Approves Brexucabtagene Autoleucel for Patients With R/R Mantle Cell Lymphoma

04/21/2026

Michael Wang, MD

Michael Wang, MD, discusses the recent FDA approval of brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses the...

04/21/2026

Oncology

Videos

Evolving Role of CAR-T and Bispecific Therapies in Chronic Lymphocytic Leukemia

04/21/2026

Javier Pinilla-Ibarz, MD, PhD

Javier Pinilla Ibarz, MD, PhD, discusses the evolving role of CAR T-cell therapy and bispecific antibodies in chronic lymphocytic leukemia.

Javier Pinilla Ibarz, MD, PhD,...

04/21/2026

Oncology

Videos

Next-Generation BTK Degraders for Patients With Chronic Lymphocytic Leukemia

04/21/2026

Justin Taylor, MD

Justin Taylor, MD, discusses the emerging role of Bruton's tyrosine kinase degrader therapies in chronic lymphocytic leukemia.

Justin Taylor, MD, discusses the...

04/21/2026

Oncology

Insights From the ASCO Annual Meeting

Conference Coverage

Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis

09/03/2025

Raajit Rampal, MD, PhD

Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.

Raajit Rampal, MD, PhD shares...

09/03/2025

Oncology

Videos

Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer

08/21/2025

John Strickler, MD

John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.

John Strickler, MD, discusses...

08/21/2025

Oncology

Conference Coverage

Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML

08/20/2025

Amer Zeidan, MBBS

Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.

Amer Zeidan, MBBS, MHS, shares...

08/20/2025

Oncology

Conference Coverage

Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma

08/12/2025

Meghan Mooradian, MD

Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.

Meghan Mooradian, MD, discusses...

08/12/2025

Oncology

Conference Coverage

Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer

08/12/2025

Nicholas James, MD

Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...

Nick James, MD, PhD, discusses...

08/12/2025

Oncology

Conference Coverage

Intracerebroventricular Delivery of CART-EGFR-IL13Rα2 Demonstrates Promise Among Patients With Recurrent Glioblastoma

08/05/2025

Stephen Bagley, MD

Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.

Stephen Bagley, MD, discusses...

08/05/2025

Oncology

Conference Coverage

First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases

07/24/2025

Zeynep Eroglu, MD

Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...

Zeynep Eroglu, MD, discusses...

07/24/2025

Oncology

Conference Coverage

BAY 2927088 Demonstrates Promise Among Patients With HER2-Mutated Non-Small Cell Lung Cancer

07/24/2025

Herbert Loong, MD

Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.

Herbert Loong, MD, discusses...

07/24/2025

Oncology

Conference Coverage

Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma

07/24/2025

Georgina Long, MBBS, PhD

Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...

Georgina Long, MD, PhD,...

07/24/2025

Oncology

Conference Coverage

Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma

07/24/2025

Alexander Van Akkooi, MD, PhD

Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.

Alexander Van Akkooi, MD, PhD,...

07/24/2025

Oncology

Insights From the ESMO Congress

Videos

Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer

12/02/2025

Stephen J. Freedland, MD

Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.

Stephen Freedland, MD, discusses...

12/02/2025

Oncology

Videos

Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer

12/02/2025

Brian M. Slomovitz, MD, MS

Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

Brian Slomovitz, MD, discusses...

12/02/2025

Oncology

Videos

Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC

12/02/2025

Pasi Jänne, MD, PhD

Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.

Pasi Jänne, MD, PhD, discusses...

12/02/2025

Oncology

Videos

Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer

12/02/2025

David Goldstein, MD

David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.

David Goldstein, MD, discusses...

12/02/2025

Oncology

Videos

Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer

11/13/2025

Sara Lonardi, MD

Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.

Sara Lonardi, MD, shares updated...

11/13/2025

Oncology

Videos

First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC

11/13/2025

Sanjay Popat, MD

Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.

Sanjay Popat, MD, PhD, discusses...

11/13/2025

Oncology

Videos

Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma

11/10/2025

Janice Mehnert, MD

Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.

Janice Mehnert, MD, discusses...

11/10/2025

Oncology

Videos

MCED Blood Test Detects Cancer Early With High Accuracy

11/10/2025

Nima Nabavizadeh, MD

Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.

Nima Nabavizadeh, MD, discusses...

11/10/2025

Oncology

Videos

Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer

11/10/2025

Maria De Santis, MD

Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.

Maria De Santis, MD, discusses...

11/10/2025

Oncology

Videos

Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma

11/10/2025

Dean Fennell, MD, PhD

Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.

Dean Fennell, MD, PhD, discusses...

11/10/2025

Oncology

Live Meetings

Recent News

News

Lorlatinib Shows Real-World Promise in in ALK-Positive Non-Small Cell Lung Cancer

04/24/2026

Emily Estrada

Real-world data demonstrate that lorlatinib provides high response and durable disease control in advanced ALK-positive NSCLC, with exploratory lipid biomarkers potentially predicting response.

Real-world data demonstrate that...

04/24/2026

Oncology

News

Mirvetuximab Plus Carboplatin Demonstrates Promise in Platinum-Sensitive Ovarian Cancer

04/21/2026

Stephanie Holland

Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.

Results from the phase 2...

04/21/2026

Oncology

News

Mocertatug Rezetecan Shows Promising Efficacy, Manageable Safety in Ovarian and Endometrial Cancer

04/21/2026

Stephanie Holland

Results from the phase 1 BEHOLD-1 study demonstrate that mocertatug rezetecan shows clinical promise among patients with platinum-resistant ovarian cancer and recurrent endometrial cancer.

Results from the phase 1...

04/21/2026

Oncology

News

Camizestrant Plus Capivasertib Shows Promise in ER-Positive, HER2-Negative Advanced Breast Cancer

04/17/2026

Emily Estrada

Results from the SERENA-1 trial demonstrate that camizestrant plus capivasertib shows strong clinical promise in endocrine-resistant patients with ER-positive, HER2-negative advanced breast cancer.

Results from the SERENA-1 trial...

04/17/2026

Oncology

News

R-CHOP-Like Therapy Retreatment Yields Durable Responses in Late-Relapsing Diffuse Large B-Cell Lymphoma

04/17/2026

Emily Estrada

In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...

In older patients with...

04/17/2026

Oncology

News

LB-100 Plus Dostarlimab Shows Clinical Promise in Platinum-Resistant Ovarian Clear Cell Carcinoma

04/15/2026

Emily Estrada

Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...

Results from an ongoing, phase...

04/15/2026

Oncology

News

Longitudinal ctDNA Clearance Predicts Outcomes in Advanced Ovarian Cancer

04/15/2026

Emily Estrada

Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.

Results from a prospective...

04/15/2026

Oncology

News

Chemotherapy Followed by Letrozole Maintains Advantage Over Letrozole Alone in Low-Grade Serous Carcinoma

04/14/2026

Stephanie Holland

Results from the phase 3 NRG-GY019 trial confirm that letrozole alone is inferior to chemotherapy followed by letrozole among patients with low-grade serous carcinomas.

Results from the phase 3...

04/14/2026

Oncology

News

Relacorilant Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer

04/13/2026

Stephanie Holland

Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.

Final overall survival results...

04/13/2026

Oncology

News

Maintenance Carfilzomib Plus Lenalidomide and Dexamethasone Following Autologous HSCT for Newly Diagnosed Multiple Myeloma

04/10/2026

Stephanie Holland

Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.

Results from the phase 3 ATLAS...

04/10/2026

Oncology